Amundi Pioneer Asset Management Inc. Has $358.72 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

Amundi Pioneer Asset Management Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 43.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,157,567 shares of the biopharmaceutical company’s stock after purchasing an additional 1,858,416 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.49% of Gilead Sciences worth $358,717,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Greylin Investment Mangement Inc. increased its holdings in shares of Gilead Sciences by 11.6% in the fourth quarter. Greylin Investment Mangement Inc. now owns 96,969 shares of the biopharmaceutical company’s stock valued at $5,649,000 after purchasing an additional 10,103 shares during the last quarter. Monarch Capital Management Inc. boosted its position in shares of Gilead Sciences by 2.9% in the fourth quarter. Monarch Capital Management Inc. now owns 67,369 shares of the biopharmaceutical company’s stock valued at $3,925,000 after acquiring an additional 1,888 shares during the period. Kestra Private Wealth Services LLC boosted its position in shares of Gilead Sciences by 71.2% in the fourth quarter. Kestra Private Wealth Services LLC now owns 38,271 shares of the biopharmaceutical company’s stock valued at $2,168,000 after acquiring an additional 15,917 shares during the period. LS Investment Advisors LLC boosted its position in shares of Gilead Sciences by 3.1% in the fourth quarter. LS Investment Advisors LLC now owns 61,892 shares of the biopharmaceutical company’s stock valued at $3,606,000 after acquiring an additional 1,881 shares during the period. Finally, Kempen Capital Management N.V. boosted its position in shares of Gilead Sciences by 22.0% in the fourth quarter. Kempen Capital Management N.V. now owns 345,770 shares of the biopharmaceutical company’s stock valued at $20,144,000 after acquiring an additional 62,378 shares during the period. Hedge funds and other institutional investors own 76.36% of the company’s stock.

A number of brokerages have recently issued reports on GILD. Guggenheim raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Monday, January 4th. Credit Suisse Group boosted their target price on shares of Gilead Sciences from $65.00 to $66.00 and gave the company a “neutral” rating in a research report on Friday, February 5th. Sanford C. Bernstein raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research report on Thursday, April 1st. Redburn Partners raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 30th. Finally, Morgan Stanley upped their price objective on shares of Gilead Sciences from $83.00 to $87.00 and gave the stock an “overweight” rating in a research report on Friday, February 5th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $96.04.

GILD stock opened at $65.60 on Thursday. The stock has a market capitalization of $82.59 billion, a P/E ratio of 67.63, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65. Gilead Sciences, Inc. has a 12 month low of $56.56 and a 12 month high of $85.79. The firm has a 50-day moving average price of $64.21 and a 200-day moving average price of $62.46.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.15 by $0.04. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. The company had revenue of $7.42 billion during the quarter, compared to the consensus estimate of $7.11 billion. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 30th. Stockholders of record on Monday, March 15th were paid a $0.71 dividend. The ex-dividend date was Friday, March 12th. This represents a $2.84 annualized dividend and a dividend yield of 4.33%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.68. Gilead Sciences’s dividend payout ratio is currently 46.25%.

In other news, EVP Brett A. Pletcher sold 1,975 shares of the company’s stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the transaction, the executive vice president now owns 28,832 shares of the company’s stock, valued at $1,943,565.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Brett A. Pletcher sold 1,486 shares of the stock in a transaction that occurred on Thursday, March 11th. The shares were sold at an average price of $63.36, for a total transaction of $94,152.96. Following the sale, the executive vice president now directly owns 29,166 shares of the company’s stock, valued at approximately $1,847,957.76. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Recommended Story: Call Option Volume

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.